4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Anbio Biotechnology (NNNN) operates in the Medical Instruments & Supplies industry and is headquartered in Frankfurt am Main, Germany with about 27 employees. Its market capitalization is roughly $418 million. In the fiscal year ended 2025-12-31, NNNN reported $9M in revenue and $6M in net income.
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
Interactive charts & full statements → Open the NNNN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $9M | $8M | $7M | $24M | — |
| Gross Profit | $8M | $6M | $3M | $13M | — |
| Operating Income (EBIT) | $6M | $2M | $2M | $10M | — |
| Net Income | $6M | $2M | $2M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $30M | $19M | $16M | $14M | — |
| Total Liabilities | $0M | $2M | $1M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NNNN viewer.
About TickerBase · Data methodology & sources